The CEO Diary with Fexingo · 2026-07-12 · 10 min
In this episode, Lucas and Luna dive into the story of Novo Nordisk, the Danish pharmaceutical giant that has become the world's most valuable company in Europe by dominating the weight loss drug market with Ozempic and Wegovy. They explore how CEO Lars Fruergaard Jørgensen navigated supply shortages, regulatory hurdles, and public scrutiny, while maintaining a purpose-driven culture. The hosts discuss the company's unconventional origins as a insulin maker, its shift into GLP-1 drugs, and the strategic decisions that led to a market cap exceeding $600 billion. Along the way, they examine the ethical dilemmas of pricing, access, and the thin line between treatment and lifestyle drug. A compelling look at leadership, innovation, and the business of changing global health. #NovoNordisk #Ozempic #Wegovy #GLP1 #WeightLossDrugs #Obesity #Pharma #Business #CEO #LarsFruergaardJorgensen #Leadership #Denmark #Healthcare #Innovation #SupplyChain #FexingoBusiness #BusinessPodcast #TheCEODiary Keep every episode free: buymeacoffee.com/fexingo
Other episodes covering the same guests and topics, from across The B2B Podcast Index.